238 related articles for article (PubMed ID: 35991054)
21. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Li S; Zhang Y; Sun Z; Hu J; Fang C
Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
[TBL] [Abstract][Full Text] [Related]
22. Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy.
Bastin M; Mosbah H; Carlier A; Boudifa A; Villemain A; Hartemann A; Andreelli F
Diabetes Metab; 2020 Oct; 46(5):406-407. PubMed ID: 31034979
[No Abstract] [Full Text] [Related]
23. Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus.
Saleh AO; Taha R; Mohamed SFA; Bashir M
Eur J Case Rep Intern Med; 2021; 8(8):002756. PubMed ID: 34527623
[TBL] [Abstract][Full Text] [Related]
24. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
Sakaguchi C; Ashida K; Yano S; Ohe K; Wada N; Hasuzawa N; Matsuda Y; Sakamoto S; Sakamoto R; Uchi H; Furue M; Nomura M; Ogawa Y
Curr Oncol; 2019 Feb; 26(1):e115-e118. PubMed ID: 30853818
[TBL] [Abstract][Full Text] [Related]
25. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
26. Type 1 diabetes related to immune checkpoint inhibitors.
Tachibana M; Imagawa A
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101657. PubMed ID: 35450793
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
28. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
29. Rapid onset type 1 diabetes with anti-PD-1 directed therapy.
Yun K; Daniels G; Gold K; Mccowen K; Patel SP
Oncotarget; 2020 Jul; 11(28):2740-2746. PubMed ID: 32733645
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
31. A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.
Tang Y; Zhao Z; Wang X; Zuo W; Zhang B; Yuan T; Fu Y
Immunotherapy; 2021 Apr; 13(6):483-489. PubMed ID: 33626915
[TBL] [Abstract][Full Text] [Related]
32. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
34. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
35. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
[TBL] [Abstract][Full Text] [Related]
36. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma.
Yamaguchi H; Miyoshi Y; Uehara Y; Fujii K; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
Diabetol Int; 2021 Apr; 12(2):234-240. PubMed ID: 33786278
[TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
Qiu JL; Luo SM; Yin WF; Li X; Zhou ZG
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(1):38-41. PubMed ID: 36594136
[TBL] [Abstract][Full Text] [Related]
38. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
Munakata W; Ohashi K; Yamauchi N; Tobinai K
Int J Hematol; 2017 Mar; 105(3):383-386. PubMed ID: 27696192
[TBL] [Abstract][Full Text] [Related]
39. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.
Lo Preiato V; Salvagni S; Ricci C; Ardizzoni A; Pagotto U; Pelusi C
Rev Endocr Metab Disord; 2021 Jun; 22(2):337-349. PubMed ID: 33409866
[TBL] [Abstract][Full Text] [Related]
40. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
